罗沙司他对腹膜透析合并贫血患者贫血指标和铁代谢指标的影响

The Effect of Rosuvastatin on Anemia Indicators and Iron Metabolism Indicators in Peritoneal Dialysis Patients with Anemia

目的探讨罗沙司他对腹膜透析(PD)合并肾性贫血(RA)患者贫血指标和铁代谢指标的影响。方法选取PD合并RA患者94例随机分为对照组(47例)与罗沙司他组(47例),分别予以人促红素注射液、罗沙司他胶囊治疗,均治疗12周。于治疗前和治疗后比较两组各项指标差异和疗效,并对不良反应进行统计分析。结果相比对照组(76.60%),罗沙司他组治疗总有效率(91.49%)更高(P<0.05)。治疗后,两组Hb、RBC和Hct水平均增高(P<0.05),且相比对照组,罗沙司他组Hb、RBC和Hct水平升高更明显,差异有统计学意义(P<0.05)。治疗后,两组铁蛋白水平降低(P<0.05),转铁蛋白和TAST水平增高(P<0.05),且相比对照组,罗沙司他组铁蛋白水平降低更明显,转铁蛋白和TAST水平升高更明显,差异有统计学意义(P<0.05)。罗沙司他组出现恶心、腹泻、头晕及血栓的不良反应发生率为6.38%,与对照组的21.28%相比明显下降,差异有统计学意义(P<0.05)。结论罗沙司他治疗PD合并RA患者能够有效纠正患者贫血指标,改善铁代谢,效果和安全性均优于人促红素注射液。

Objective To explore the effects of rosuvastatin on anemia and iron metabolism indicators of patients with peritoneal dialysis(PD)complicated with renal anemia(RA).Methods 94 patients with PD combined with RA were randomly divided into the control group(47)and the rosuvastatin group(47).They were treated with erythropoietin injection and rosuvastatin capsules,respectively,for 12 weeks.We compared the differences in various indicators and therapeutic effects between the two groups before and after treatment,and conduct statistical analysis on adverse reactions.Results Compared with the control group,the total effective rate of treatment in the rosuvastatin group was higher(P<0.05).After treatment,the levels of Hb,RBC,and Hct were higher in the rosuvastatin group compared to the control group(P<0.05).After treatment,compared to the control group,the rosuvastatin group had lower levels of ferritin(P<0.05)and higher levels of transferrin and TAST(P<0.05).The incidence of adverse reactions in the rosuvastatin group was 6.38%,which was significantly lower compared to the control group's 21.28%(P<0.05).Conclusion Rosuvastatin can effectively correct anemia indicators and improve iron metabolism of patients with PD complicated with RA,and its efficacy and safety are better than those of erythropoietin injection.